Rhys G Morgan
LGR5 expression is regulated by EGF in early colorectal adenomas and governs EGFR inhibitor sensitivity
Morgan, Rhys G; Mortensson, Eleanor; Legge, Danny N; Gupta, B.; Collard, Tracey J; Greenhough, Alexander; Williams, Ann C
Authors
Eleanor Mortensson
Danny N Legge
B. Gupta
Tracey J Collard
Alexander Greenhough Alexander.Greenhough@uwe.ac.uk
Associate Professor of Health Diagnostics
Ann C Williams
Abstract
© The Author(s) named above 2018. Background:LGR5 serves as a co-receptor for Wnt/β-catenin signalling and marks normal intestinal stem cells; however, its role in colorectal cancer (CRC) remains controversial. LGR5 + cells are known to exist outside the stem cell niche during CRC progression, and the requirement for epidermal growth factor (EGF) signalling within early adenomas remains to be fully elucidated.Methods:Epidermal growth factor and gefitinib treatments were performed in EGF-responsive LGR5 + early adenoma RG/C2 cells. 2D growth assays were measured using an IncuCyte. LGR5 or MEK1/2 silencing studies were executed using siRNA and LGR5 expression was assessed by qRT-PCR and immunoblotting. Ki67 level and cell cycle status were analysed by flow cytometry.Results:Epidermal growth factor suppresses expression of LGR5 at both the transcript and protein level in colorectal adenoma and carcinoma cells. Suppression of LGR5 reduces the survival of EGF-treated adenoma cells by increasing detached cell yield but also inducing a proliferative state, as evidenced by elevated Ki67 level and enhanced cell cycle progression. Repression of LGR5 further increases the sensitivity of adenoma cells to EGFR inhibition.Conclusions:LGR5 has an important role in the EGF-mediated survival and proliferation of early adenoma cells and could have clinical utility in predicting response of CRC patients to EGFR therapy.
Journal Article Type | Article |
---|---|
Acceptance Date | Oct 19, 2017 |
Online Publication Date | Nov 16, 2017 |
Publication Date | Feb 20, 2018 |
Deposit Date | Feb 12, 2019 |
Publicly Available Date | Feb 14, 2019 |
Journal | British Journal of Cancer |
Print ISSN | 0007-0920 |
Electronic ISSN | 1532-1827 |
Publisher | Springer Nature [academic journals on nature.com] |
Peer Reviewed | Peer Reviewed |
Volume | 118 |
Issue | 4 |
Pages | 558-565 |
DOI | https://doi.org/10.1038/bjc.2017.412 |
Public URL | https://uwe-repository.worktribe.com/output/871357 |
Publisher URL | https://doi.org/10.1038/bjc.2017.412 |
Contract Date | Feb 12, 2019 |
Files
bjc2017412.pdf
(1.7 Mb)
PDF
You might also like
Anticancer effects of the Novel Pyrazolyl-Urea GeGe-3
(2024)
Journal Article
BCL–3 promotes cyclooxygenase–2/prostaglandin E2 signalling in colorectal cancer
(2020)
Journal Article
Downloadable Citations
About UWE Bristol Research Repository
Administrator e-mail: repository@uwe.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2024
Advanced Search